Methods of treating or preventing erectile dysfunction
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/136
A61K-031/44
출원번호
US-0395298
(2003-03-25)
발명자
/ 주소
Jerussi,Thomas P
Senanayake,Chrisantha H.
Fang,Qun K.
출원인 / 주소
Sepracor Inc.
대리인 / 주소
Jones Day
인용정보
피인용 횟수 :
0인용 특허 :
31
초록▼
Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disord
Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.
대표청구항▼
What is claimed is: 1. A method of treating erectile dysfunction which comprises adjunctively administering to a patient in need of such treatment a therapeutically effective amounts of a dopamine reuptake inhibitor and a 5-HT3 antagonist. 2. The method of claim 1 wherein the dopamine reuptake in
What is claimed is: 1. A method of treating erectile dysfunction which comprises adjunctively administering to a patient in need of such treatment a therapeutically effective amounts of a dopamine reuptake inhibitor and a 5-HT3 antagonist. 2. The method of claim 1 wherein the dopamine reuptake inhibitor is a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. 3. The method of claim 2 wherein the sibutramine metabolite is (+)-desmethylsibutramine, (-)-desmethylsibutramine, (짹)-desmethylsibutramine, (+)-didesmethylsibutramine, (-)-didesmethylsibutramine, or (짹)-didesmethylsibutramine. 4. The method of claim 3 wherein the amount of sibutramine metabolite administered is from about 0.1 mg to about 60 mg/day. 5. The method of claim 4 wherein the amount of sibutramine metabolite administered is from about 2 mg to about 30 mg/day. 6. The method of claim 5 wherein the amount of sibutramine metabolite administered is from about 5 mg to about 15 mg/day. 7. The method of claim 3, wherein the sibutramine metabolite is optically pure (+)-desmethylsibutramine or (+)-didesmethylsibutramine. 8. The method of claim 7, wherein the sibutramine metabolite is optically pure (+)-didesmethylsibutramine. 9. The method of claim 3, wherein the sibutramine metabolite is optically pure (-)-desmethylsibutramine or (-)-didesmethylsibutramine. 10. The method of claim 9, wherein the sibutramine metabolite is optically pure (-)-didesmethylsibutramine. 11. The method of claim 1 wherein the 5-HT3 antagonist is an antiemetic agent. 12. The method of claim 1 wherein the 5-HT3 antagonist is granisetron, metoclopramide, ondansetron, renzapride, zacopride, tropisetron, or an optically pure stereoisomer, active metabolite, or a pharmaceutically acceptable salt, clathrate, or solvate thereof. 13. The method of claim 1 wherein the dopamine uptake inhibitor and/or the 5-HT3 antagonist is administered transdermally or mucosally. 14. A method of treating erectile dysfunction which comprises administering to a patient in need of such treatment a therapeutically effective amount of a racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. 15. The method of claim 14 wherein the sibutramine metabolite is (+)-desmethylsibutramine, (-)-desmethylsibutramine, (짹)-desmethylsibutramine, (+)-didesmethylsibutramine, (-)-didesmethylsibutramine, or (짹)-didesmethylsibutramine. 16. The method of claim 15, wherein the sibutramine metabolite is optically pure (+)-desmethylsibutramine or (+)-didesmethylsibutramine. 17. The method of claim 16, wherein the sibutramine metabolite is optically pure (+)-didesmethylsibutramine. 18. The method of claim 15, wherein the sibutramine metabolite is optically pure (-)-desmethylsibutramine or (-)-didesmethylsibutramine. 19. The method of claim 18, wherein the sibutramine metabolite is optically pure (-)-didesmethylsibutramine. 20. The method of claim 14 wherein the sibutramine metabolite is administered transdermally or mucosally.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (31)
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Marshall Lucia G. I. (St. Charles MO) Patel Kanaiyalal R. (St. Louis MO) Roufa Dikla G. (St. Louis MO), Controlled release formulations of trophic factors in ganglioside-lipsome vehicle.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Doherty ; Jr. Paul C. ; Place Virgil A. ; Smith William L., Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Eswara Amruta R. ; Muni Neal ; Schneider F. Howard ; Mione Peter J., Methods and articles of manufacture for nicotine cessation and monitoring nicotine use.
Le Grazie Cristina (Milan ITX), Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutic.
Jeffery James E. (Nottingham GB2) Whybrow Derek (Nottingham GB2), Process for the manufacture of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrat.
Abou-Gharbia Magid A. (Glen Mills PA) Yardley John P. (Gulph Mills PA) Cliffe Ian A. (Slough GBX), Tertiary alkyl functionalized piperazine derivatives.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.